Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights
US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical...
Nurix Therapeutics
Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program
US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership...
Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation
France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics...